Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol

Abstract

Chemical inhibitors of cyclin-dependent kinases (CDKs) have a great therapeutic potential against various proliferative and neurodegenerative disorders. Intensive screening of a combinatorial chemistry library of 2,6,9-trisubstituted purines has led to the identification of purvalanol, one of the most potent and selective CDK inhibitors to date. In preliminary studies, this compound demonstrates definite anti-mitotic properties, consistent with its nanomolar range efficiency towards purified CDK1 and CDK2. However, the actual intracellular targets of purvalanol remain to be identified, and a method for the determination of its in vivo selectivity was developed. In this technique, cell extracts were screened for purvalanol-interacting proteins by affinity chromatography on immobilized inhibitor. In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction. The Chinese hamster lung fibroblast cell line CCL39 was used as a model to investigate the anti-proliferative properties of purvalanol. The compound inhibited cell growth with a GI50 value of 2.5 μM and induced a G2/M block when added to exponentially growing cells. It did not appear to trigger massive activation of caspase. We next tested whether CDKs and p42/p44 MAPK were actually targeted by the compound in vivo. p42/p44 MAPK activity was visualized using an Elk–Gal4 luciferase reporter system and CDK1 activity was detected by the phosphonucleolin level. When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner. Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases. We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs. These observations highlight the potency of moderate selectivity compounds and encourage the search for new therapeutics which simultaneously target distinct but relevant pathways of cell proliferation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant BT, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble MEM, Sausville EA, Schultz R, Yu W . 2000 J. Med. Chem. 43: 2797–2804

  • Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E . 2000 J. Med. Chem. 43: 4606–4613

  • Borgne A, Meijer L . 1996 J. Biol. Chem. 271: 27847–27854

  • Brooks EE, Gray NS, Joly A, Kerwar SS, Lum R, Mackman RL, Norman TC, Rosete J, Rowe M, Schow SR, Schultz PG, Wang X, Wick MM, Shiffman D . 1997 J. Biol. Chem. 272: 29207–29211

  • Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J . 1999 EMBO J. 18: 664–674

  • Carini DJ, Kaltenbach RF, Liu J, Benfield PA, Boylan J, Boisclair M, Brizuela L, Burton CR, Cox S, Grafstrom R, Harrison BA, Harrison K, Akamike E, Markwalder JA, Nakano Y, Seitz SP, Sharp DM, Trainor GL, Sielecki TM . 2001 Bioorg. Med. Chem. Lett. 11: 2209–2211

  • Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG . 1999 Chem. Biol. 6: 361–375

  • Clare PM, Poorman RA, Kelley LC, Watenpaugh KD, Bannow CA, Leach KL . 2001 J. Biol. Chem. 276: 48292–48299

  • Damiens E, Meijer L . 2000 Pathol. Biol. 48: 340–351

  • Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH, Kuyper LF . 2001 Science 291: 134–137

  • de Azevedo WF, Leclerc S, Miejer L, Havlicek L, Strnad M, Kim SH . 1997 Eur. J. Biochem. 243: 518–526

  • Dranovsky A, Vincent I, Gregori L, Schwarzman A, Colflesh D, Enghild J, Strittmatter W, Davies P, Goldgaber D . 2001 Neurobiol. Aging 22: 517–528

  • Dreyer MK, Borcherding DR, Dumont JA, Peet NP, Tsay JT, Wright PS, Bitonti AJ, Shen J, Kim SH . 2001 J. Med. Chem. 44: 524–530

  • Dunphy WG . 1997 Meth. Enzymol. 283: 1–678

  • Edelmann HM, Kuhne C, Petritsch C, Ballou LM . 1996 J. Biol. Chem. 271: 963–971

  • Fischer PM, Lane DP . 2000 Curr. Med. Chem. 7: 1213–1245

  • Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD . 2001 J. Biol. Chem. 276: 16617–16623

  • Garrett MD, Fattaey A . 1999 Curr. Opin. Genet. Dev. 9: 104–111

  • Gille H, Sharrocks AD, Shaw PE . 1992 Nature 358: 414–417

  • Gray N, Detivaud L, Doerig C, Meijer L . 1999 Curr. Med. Chem. 6: 859–875

  • Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, Leclerc S, Meijer L, Kim SH, Lockhard DJ, Schultz PG . 1998 Science 281: 533–538

  • Hardcastle IR, Golding BT, Griffin RJ . 2002 Annu. Rev. Pharmacol. Toxicol. 42: 325–348

  • Herrera R, Sebolt-Leopold JS . 2002 Trends Mol. Med 8: S27–S31

  • Hoebeke J, Van Nijen G, De Brabander M . 1976 Biochem. Biophys. Res. Commun. 69: 319–324

  • Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L . 1999 Nat. Cell Biol. 1: 60–67

  • Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M . 1999 Oncogene 18: 813–822

  • Janknecht R, Ernst WH, Pingoud V, Nordheim A . 1993 EMBO J. 12: 5097–5104

  • Jeong HW, Kim MRR, Son KH, Han MY, Ha JH, Garnier M, Meijer L, Kwon BM . 2000 Biorg. Med. Chem. Lett. 10: 1819–1822

  • Kaiser A, Nishi K, Gorin FA, Walsh DA, Bradbury EM, Schnier JB . 2001 Arch. Biochem. Biophys. 386: 179–187

  • Kaubisch A, Schwartz GK . 2000 Cancer J. 6: 192–212

  • Keenan SM, Bellone C, Baldassare JJX . 2001 J. Biol. Chem. 276: 22404–22409

  • Kent LL, Hull-Campbell NE, Lau T, Wu JC, Thompson SA, Nori M . 1999 Biochem. Biophys. Res. Commun. 260: 768–774

  • Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tamaka N, Okuyama A . 1993 Oncogene 8: 2425–2432

  • Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L . 2000 Chem. Biol. 7: 411–422

  • Knockaert M, Greengard P, Meijer L . 2002a Trends Pharmacol. Sci. (in press)

  • Knockaert M, Wieking K, Schmitt S, Leost M, Mottram J, Kunick C, Meijer L . 2002b J. Biol. Chem. 277: 25493–25501

  • Lane ME, Uu B, Rice A, Lipson KE, Liang C, Sun L, Tang C, McMahon G, Pestell RG, Wadler S . 2001 Cancer Res. 61: 6170–6177

  • Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L . 2001 J. Biol. Chem. 276: 251–260

  • Legraverend M, Noble M, Tunnah P, Ducrot P, Ludwig O, Leclerc S, Grierson DS, Meijer L, Endicott J . 2000 J. Med. Chem. 43: 1282–1292

  • Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, Pouyssegur J . 1993 J. Cell Biol. 122: 1079–1088

  • Lenormand P, McMahon M, Pouyssegur J . 1996 J. Biol. Chem. 271: 15762–15768

  • Lenormand P, Brondello JM, Brunet A, Pouyssegur J . 1998 J. Cell Biol. 142: 625–633

  • Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, Gussio R, Senderowicz AM, Sausville EA, Kunick C, Meijer L . 2000 Eur. J. Biochem. 267: 5983–5994

  • Losiewicz MD, Carison BA, Kaur G, Sausville EA, Worland PJ . 1994 Biochem. Biophys. Res. Commun. 201: 589–595

  • Malumbres M, Ortega S, Barbacid M . 2000 Biol. Chem. 381: 827–838

  • Mani S, Wang C, Wu K, Francis R, Pestell R . 2000 Expert Opin. Investig. Drugs 9: 1849–1870

  • Marais R, Wynne J, Treisman R . 1993 Cell 73: 381–393

  • Meijer L . 2000 Drug resist Updat 3: 83–88

  • Meijer L, Kim SH . 1997 Methods Enzymol. 283: 113–128

  • Meijer L, Pondaven P . 1988 Exp. Cell Res. 174: 116–129

  • Meijer L, Borgne A, Muler O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP . 1997 Eur. J. Biochem. 243: 527–536

  • Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR . 2000 Chem. Biol. 7: 51–63

  • Meloche S, Pages G, Pouyssegur J . 1992 Mol. Biol. Cell 3: 63–71

  • Milanini J, Vinals F, Pouyssegur J, Pages G . 1998 J. Biol. Chem. 273: 18165–18172

  • Morgan DO . 1997 Annu. Rev. Cell. Dev. Biol. 13: 261–291

  • Neant I, Guerrier P . 1988 Exp. Cell Res. 176: 68–79

  • Nugiel DA, Etzkorn AM, Vidwans A, Benfield PA, Boisclair M, Burton CR, Cox S, Czerniak PM, Doleniak D, Seitz SP . 2001 J. Med. Chem. 44: 1334–1336

  • Oikonomakos NG, Schnier JB, Zographos SE, Skamnaki VT, Tsitsanou KE, Johnson LN . 2000 J. Biol. Chem. 275: 34566–34573

  • Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J . 1993 Proc. Natl. Acad. Sci. USA 90: 8319–8323

  • Park SG, Cheon JY, Lee YH, Park JS, Lee KY, Lee CH, Lee SK . 1996 Mol. Cells 6: 679–683

  • Parker CW, Entsch B, Letham DS . 1986 Phytochemistry 25: 303–310

  • Pavletich NP . 1999 J. Mol. Biol. 287: 821–828

  • Rialet V, Meijer L . 1991 Anticancer Res. 11: 1581–1590

  • Rosania GR, Chang T . 2000 Exp. Opin. Ther. Patents 10: 1–16

  • Rosania GR, Merlie Jr J, Gray N, Chang YT, Schultz PG, Heald R . 1999 Proc. Natl. Acad. Sci. USA 96: 4797–4802

  • Samuels ML, Weber MJ, Bishop M, McMahon M . 1993 Mol. Cell. Biol. 13: 6241–6252

  • Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malin M, Gray N, Schaffer PA . 2002 J. Virol. 76: 7874–7882

  • Schnier JB, Kaur G, Kaiser A, Stinson SF, Sausville EA, Gardner J, Nishi K, Bradbury EM, Senderowicz AM . 1999 FEBS Lett. 454: 100–104

  • Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L, Kunick C . 1999 J. Med. Chem. 42: 2909–2919

  • Schultze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH . 1995 Proteins – Struct. Funct. Genet. 22: 378–391

  • Sebolt-Leopold JS . 2000 Oncogene 19: 6594–6599

  • Senderowicz AM, Sausville EA . 2000 J. Natl. Cancer Inst. 92: 376–387

  • Shapiro PS, Vaisberg E, Hunt AJ, Tolwinski NS, Whalen AM, McIntosh JR, Ahn NG . 1998 J. Cell Biol. 142: 1533–1545

  • Sherwood SW, Sheridan JP, Schimke RT . 1994 Exp. Cell Growth Differ. 215: 373–379

  • Shewchuk L, Hassell A, Wisely B, Rocque W, Holmes W, Veal J, Kuyper LF . 2000 J. Med. Chem. 43: 133–138

  • Shum PW, Peet NP, Weintraub PM, Le TB, Zhao Z, Barbone F, Cashman B, Tsay J, Dwyer S, Loos PC, Powers EA, Kropp K, Wright PS, Bitonti A, Dumont J, Borcherding DR . 2001 Nucleosides Nucleotides Nucleic Acids 20: 1067–1078

  • Sielecki TM, Boylan JF, Benfield PA, Trainor GL . 2000 J. Med. Chem. 43: 118

  • Sielecki TM, Johnson TL, Liu J, Muckelbauer JK, Grafstrom RH, Cox S, Boylan J, Burton CR, Chen H, Smallwood A, Chang CH, Boisclair M, Benfield PA, Traimor GL, Seitz SP . 2001 Biorganic Medic. Chem. Lett. 11: 1157–1160

  • Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B . 2000 Biochem. Biophys. Res. Commun. 275: 877–884

  • Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B . 2001 J. Natl. Cancer Inst. 21: 436–446

  • Toogood PL . 2001 Med. Res. Rev. 21: 487–498

  • Urbani L, Sherwood SW, Schimke RT . 1995 Exp. Cell Res. 219: 159–168

  • Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S, Meijer L . 1994 Eur. J. Biochem. 224: 771–786

  • Villerbu N, Gaben AM, Redeuilh G, Mester J . 2002 Int. J. Cancer 97: 761–769

  • Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang FM, McCubrey JA . 2000 Pharmacol. Ther 88: 229–279

  • Wright JH, Munar E, Jameson DR, Andreassen PR, Margolis RL, Seger R, Krebs EG . 1999 Proc. Natl. Acad. Sci. USA 96: 11335–11340

  • Yu C, Wang S, Dent P, Grant S . 2001 Mol. Pharmacol. 60: 143–154

  • Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA . 1999 Cancer Res. 59: 2566–2569

  • Zimmermann J . 1995 Pharmacologically active pyrimidine derivatives and processes for the preparation thereof. PCT Ciba-Geigy, WO 95/09853

Download references

Acknowledgements

We would like to thank our colleagues for providing reagents and help: Eve Damiens and Dominique Marie for their assistance in FACS analysis, Peter Davis for providing the TG3 antibody, Dr M Yamashita for providing the Cyclin Bcdc13 antibody and Bruce Cagnol for PARP cleavage analysis. We are grateful to Sandrine Boulben for her help with the Western blot quantification. This research was also supported by grants from the ‘Association pour la Recherche sur le Cancer’ (ARC 5343 & ARC5732) (L Meijer) and the ‘Conseil Régional de Bretagne’ (L Meijer).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Laurent Meijer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knockaert, M., Lenormand, P., Gray, N. et al. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 21, 6413–6424 (2002). https://doi.org/10.1038/sj.onc.1205908

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205908

Keywords

This article is cited by

Search

Quick links